Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease
Copyright © 2023 Elsevier Ltd. All rights reserved..
BACKGROUND: Overactive bladder (OAB) is a common non-motor symptom of Parkinson disease (PD), often treated with antimuscarinics or beta-3 agonists. There is lack of evidence to guide OAB management in PD.
OBJECTIVES: To assess the comparative safety of antimuscarinics versus beta-3 agonists for OAB treatment in PD.
METHODS: We employed a new-user, active-comparator cohort study design. We included Medicare beneficiaries age ≥65 years with PD who were new users of either antimuscarinic or beta-3 agonist. The primary outcome was any acute care encounter (i.e., non-elective hospitalization or emergency department visit) within 90 days of OAB drug initiation. The main secondary outcome was a composite measure of acute care encounters for anticholinergic related adverse events (AEs). Matching on high-dimensional propensity score (hdPS) was used to address potential confounding. We used Cox proportional hazards models to examine the association between OAB drug category and outcomes. We repeated analyses for 30- and 180-day follow-up periods.
RESULTS: We identified 27,091 individuals meeting inclusion criteria (mean age: 77.8 years). After hdPS matching, antimuscarinic users had increased risks for any acute care encounter (hazard ratio [HR] 1.23, 95% confidence interval [CI] 1.12-1.37) and encounters for anticholinergic related AEs (HR 1.18, 95% CI 1.04-1.34) compared to beta-3 agonist users. Similar associations were observed for sensitivity analyses.
CONCLUSIONS: Among persons with PD, anticholinergic initiation was associated with a higher risk of acute care encounters compared with beta-3 agonist initiation. The long-term safety of anticholinergic vs. beta-3 agonist therapy in the PD population should be evaluated in a prospective study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:115 |
|---|---|
| Enthalten in: |
Parkinsonism & related disorders - 115(2023) vom: 06. Okt., Seite 105822 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abraham, Danielle S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.10.2023 Date Revised 11.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.parkreldis.2023.105822 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362108897 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362108897 | ||
| 003 | DE-627 | ||
| 005 | 20240211231919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.parkreldis.2023.105822 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM362108897 | ||
| 035 | |a (NLM)37713748 | ||
| 035 | |a (PII)S1353-8020(23)00901-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abraham, Danielle S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative safety of antimuscarinics versus mirabegron for overactive bladder in Parkinson disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.10.2023 | ||
| 500 | |a Date Revised 11.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Overactive bladder (OAB) is a common non-motor symptom of Parkinson disease (PD), often treated with antimuscarinics or beta-3 agonists. There is lack of evidence to guide OAB management in PD | ||
| 520 | |a OBJECTIVES: To assess the comparative safety of antimuscarinics versus beta-3 agonists for OAB treatment in PD | ||
| 520 | |a METHODS: We employed a new-user, active-comparator cohort study design. We included Medicare beneficiaries age ≥65 years with PD who were new users of either antimuscarinic or beta-3 agonist. The primary outcome was any acute care encounter (i.e., non-elective hospitalization or emergency department visit) within 90 days of OAB drug initiation. The main secondary outcome was a composite measure of acute care encounters for anticholinergic related adverse events (AEs). Matching on high-dimensional propensity score (hdPS) was used to address potential confounding. We used Cox proportional hazards models to examine the association between OAB drug category and outcomes. We repeated analyses for 30- and 180-day follow-up periods | ||
| 520 | |a RESULTS: We identified 27,091 individuals meeting inclusion criteria (mean age: 77.8 years). After hdPS matching, antimuscarinic users had increased risks for any acute care encounter (hazard ratio [HR] 1.23, 95% confidence interval [CI] 1.12-1.37) and encounters for anticholinergic related AEs (HR 1.18, 95% CI 1.04-1.34) compared to beta-3 agonist users. Similar associations were observed for sensitivity analyses | ||
| 520 | |a CONCLUSIONS: Among persons with PD, anticholinergic initiation was associated with a higher risk of acute care encounters compared with beta-3 agonist initiation. The long-term safety of anticholinergic vs. beta-3 agonist therapy in the PD population should be evaluated in a prospective study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Anticholinergics | |
| 650 | 4 | |a Antimuscarinics | |
| 650 | 4 | |a Mirabegron | |
| 650 | 4 | |a Overactive bladder | |
| 650 | 4 | |a Parkinson disease | |
| 650 | 7 | |a Muscarinic Antagonists |2 NLM | |
| 650 | 7 | |a mirabegron |2 NLM | |
| 650 | 7 | |a MVR3JL3B2V |2 NLM | |
| 650 | 7 | |a Acetanilides |2 NLM | |
| 650 | 7 | |a Cholinergic Antagonists |2 NLM | |
| 650 | 7 | |a Urological Agents |2 NLM | |
| 700 | 1 | |a Pham Nguyen, Thanh Phuong |e verfasserin |4 aut | |
| 700 | 1 | |a Newcomb, Craig W |e verfasserin |4 aut | |
| 700 | 1 | |a Gray, Shelly L |e verfasserin |4 aut | |
| 700 | 1 | |a Hennessy, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Leonard, Charles E |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Weintraub, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Willis, Allison W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Parkinsonism & related disorders |d 1995 |g 115(2023) vom: 06. Okt., Seite 105822 |w (DE-627)NLM094552002 |x 1873-5126 |7 nnns |
| 773 | 1 | 8 | |g volume:115 |g year:2023 |g day:06 |g month:10 |g pages:105822 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.parkreldis.2023.105822 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 115 |j 2023 |b 06 |c 10 |h 105822 | ||